Shivakumar Venkataram, Rajasekaran Ashwini, Subbanna Manjula, Kalmady Sunil Vasu, Venugopal Deepthi, Agrawal Rimjhim, Amaresha Anekal C, Agarwal Sri Mahavir, Joseph Boban, Narayanaswamy Janardhanan C, Debnath Monojit, Venkatasubramanian Ganesan, Gangadhar Bangalore N
Department of Integrative Medicine, National Institute of Mental Health and Neuro Sciences, Bengaluru, India; Translational Psychiatry Laboratory, Cognitive Neurobiology Division, Neurobiology Research Centre, National Institute of Mental Health and Neuro Sciences, Bengaluru, India.
Translational Psychiatry Laboratory, Cognitive Neurobiology Division, Neurobiology Research Centre, National Institute of Mental Health and Neuro Sciences, Bengaluru, India; Department of Human Genetics, National Institute of Mental Health and Neuro Sciences, Bangalore, India.
Asian J Psychiatr. 2020 Oct;53:102193. doi: 10.1016/j.ajp.2020.102193. Epub 2020 Jun 5.
Schizophrenia is a complex neuropsychiatric disorder with significant genetic predisposition. In a subset of schizophrenia patients, mitochondrial dysfunction could be explained by the genomic defects like mitochondrial DNA Copy Number Variations, which are considered as a sensitive index of cellular oxidative stress. Given the high energy demands for neuronal functions, altered Mitochondrial DNA copy number (mtDNAcn) and consequent impaired mitochondrial physiology would significantly influence schizophrenia pathogenesis. In this context, we have made an attempt to study mitochondrial dysfunction in schizophrenia by assessing mtDNAcn in antipsychotic-naïve/free schizophrenia patients.
mtDNAcn was measured in 90 antipsychotic-naïve / free schizophrenia (SCZ) patients and 147 Healthy Controls (HC). The relative mtDNAcn was determined by quantitative real-time polymerase chain reaction (qPCR) using TaqMan® multiplex assay method.
A statistically significant difference between groups [t = 5.22, P < 0.001] was observed, with significantly lower mtDNAcn in SCZ compared to HC. The group differences persisted even after controlling for age and sex [F (4, 232) = 22.68, P < 0.001, η2 = 0.09].
Lower mtDNAcn in SCZ compared to HC suggests that mtDNAcn may hold potential to serve as an important proxy marker of mitochondrial function in antipsychotic-naïve/free SCZ patients.
精神分裂症是一种具有显著遗传易感性的复杂神经精神疾病。在一部分精神分裂症患者中,线粒体功能障碍可由线粒体DNA拷贝数变异等基因组缺陷来解释,这些缺陷被认为是细胞氧化应激的敏感指标。鉴于神经元功能对能量的高需求,线粒体DNA拷贝数(mtDNAcn)的改变以及随之而来的线粒体生理功能受损会显著影响精神分裂症的发病机制。在此背景下,我们试图通过评估未服用过抗精神病药物/未使用过抗精神病药物的精神分裂症患者的mtDNAcn来研究精神分裂症中的线粒体功能障碍。
对90例未服用过抗精神病药物/未使用过抗精神病药物的精神分裂症(SCZ)患者和147名健康对照者(HC)进行mtDNAcn检测。使用TaqMan®多重检测方法通过定量实时聚合酶链反应(qPCR)测定相对mtDNAcn。
观察到两组之间存在统计学显著差异[t = 5.22,P < 0.001],与健康对照者相比,精神分裂症患者的mtDNAcn显著更低。即使在控制年龄和性别后,组间差异仍然存在[F (4, 232) = 22.68,P < 0.001,η2 = 0.09]。
与健康对照者相比,精神分裂症患者的mtDNAcn较低,这表明mtDNAcn可能有潜力作为未服用过抗精神病药物/未使用过抗精神病药物的精神分裂症患者线粒体功能的重要替代标志物。